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 2 
Eukaryotic microbial pathogens are major contributors to illness and death 34 
globally but much of their impact can be controlled by drug therapy. However, 35 
as with prokaryotic microbes, the emergence of drug resistance has threatened 36 
these treatment efforts. Here, we discuss the challenges posed by eukaryotic 37 
microbial pathogens and how these are similar to, or differ from, the challenges 38 
of prokaryotic antibiotic resistance. The therapies used for several major 39 
eukaryotic microbes are then detailed and the mechanisms that they have 40 
evolved to overcome these described. The rapid emergence of resistance and 41 
the restricted pipeline of new drug therapies pose significant risks to global 42 
health and are particularly acute in the developing world.  Nonetheless, we detail 43 
how an integration of new technology, biological understanding, epidemiology 44 
and evolutionary analysis can help sustain existing therapies, anticipate the 45 
emergence of resistance or optimise the deployment of new therapies. 46 
 47 
The identification and use of antibiotics presents one of the great medical 48 
achievements of the 20th Century, saving countless lives by controlling the risk of 49 
infection from contagion, after injury, surgery or in immunosuppressed individuals. 50 
However, in only 80 years since the introduction of penicillin, resistance to a broad 51 
range of antibiotic drugs has become widespread, with the compounded risk from 52 
multi-drug resistant bacterial infections severely limiting treatment options. This has 53 
created justified concern and global attention, not only in the medical community but 54 
also at Government level, in the media and the public1. 55 
Whilst predominantly applied to control prokaryotic microbial infections, the 56 
threat of disease from eukaryotic microbes has also been contained by therapeutic 57 
drugs - preventing or controlling disease caused by eukaryotic parasites and fungi in 58 
both a human and animal health setting. These represent some of the most important 59 
disease-causing agents (Table 1), particularly in the tropics where the distribution of 60 
the pathogen is frequently linked to the distribution of the arthropods that act as 61 
disease vectors. Such vector-borne parasites include malaria (Plasmodium spp.) and 62 
kinetoplastid parasites (Trypanosoma cruzi, causing Chagas’ disease; Trypanosoma 63 
brucei gambiense and T. b. rhodesiense causing human African trypanosomiasis 64 
(HAT), and 17 Leishmania spp. causing a variety of cutaneous and visceral diseases). 65 
Other clinically important protozoan parasite species not considered in this review are 66 
transmitted either orally (Toxoplasma, Giardia and Entamoeba) or venereally 67 
(Trichomonas).  Distinct from the many obligate eukaryotic unicellular parasites, 68 
opportunistic fungal pathogens are global in distribution and include Candida, 69 
Aspergillus spp., Cryptococcus and Pneumocystis spp.  70 
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The control of these eukaryotic pathogens has often involved therapies 71 
predating the use of penicillin and in some cases with unacceptable toxicity profiles2.  72 
Nonetheless, as with the rise of antimicrobial resistance in bacteria, resistance has or 73 
is emerging in the therapies targeting these eukaryotic microbes, with potentially 74 
devastating consequences for exposed populations. This, however, has received far 75 
less attention despite some commonality in its underlying causes. In this perspective, 76 
we detail how the control of eukaryotic microbes poses both similar and distinct 77 
challenges to that of bacterial pathogens, the drugs used to combat these pathogens 78 
and the resistance mechanisms they are evolving. Finally we discuss how the latest 79 
methodological approaches can anticipate the emergence of drug resistance and 80 
support the development of new therapeutic approaches, either through the 81 
development of new drugs, the maintenance of existing therapies or through the use 82 
of alternative approaches to limit the spread of drug resistance. 83 
 84 
Common challenges for the control of prokaryotic and eukaryotic microbial 85 
pathogens. 86 
 87 
The challenges in the control of eukaryotic microbial pathogens share many similarities 88 
with bacterial infections. Both replicate more rapidly than their hosts, such that 89 
resistance can be selected within a relatively short timescale within a treated host 90 
population. This is exacerbated by inappropriate treatment profiles, leading to 91 
subcurative exposure in the context of infection3. Problems of sub optimal dosing are 92 
particularly acute when applied to tropical parasites. For example, for antimalarials, up 93 
to 35% of drugs may be of poor quality, have poor packaging and labelling or be 94 
falsified4. With lower than optimal concentrations of the active agent, this rapidly 95 
selects resistance in exposed populations, as does underdosing resulting from self-96 
prescription. Where zoonoses are concerned, such as with African trypanosomes, 97 
parasite selection in livestock populations treated with trypanocides in a context where 98 
there is poor supply chain management, fraudulent provision or cost barriers to optimal 99 
dosing, can also lead to resistance emergence. This represents a significant threat 100 
where up to 50 million doses of trypanocides are used in sub-Saharan livestock 101 
annually, mainly as a preventative, and trypanocides represent 45% of animal health 102 
costs. Agricultural use of fungicides might also contribute to the selection of azole 103 
resistant Aspergillus fumigatus5, mirroring the situation with antibiotic exposure in 104 
veterinary contexts for bacterial infections, where environmental contamination 105 
generates significant regulatory concern6.  106 
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A further similarity between bacterial and eukaryotic microbial pathogens is the 107 
phenomenon of persister populations7.  This is the survival of a fraction of the 108 
population of pathogens following exposure to a chemotherapeutic agent (or vaccine). 109 
These can then re-establish patent infection whilst remaining drug sensitive (see 110 
review8).  The state of persistence is not heritable and resistance is not due to genetic 111 
alterations directly linked to rendering a drug ineffective.  Rather, persistence is a 112 
physiologically active state involving pathogen response to the assault which is 113 
initiated upon demand.  Persistence ensures incidental survival but does not future-114 
proof a pathogen as genetically heritable resistance would. However, the combination 115 
of persisters and sub-optimal drug dosage might form an enhanced reservoir for the 116 
emergence of resistance and may even provide a population pre-disposed to evolve 117 
resistance more readily.  An example of this relating to parasite dormancy is the 118 
resistance of Plasmodium falciparum to artemisinin (and other antimalarials such as 119 
mefloquine, atovaquone), which was first characterised by degrees of persistence 120 
followed by the emergence of genomic changes now causally associated with 121 
resistance (see below). Similarly, fungal infections (e.g. C. albicans) associated with 122 
biofilms are a good example of persister populations analogous to those in bacterial 123 
communities9-11. The duration of persistence can range from days (P. falciparum) to 124 
lifelong (e.g. C. albicans).  Mechanisms of persistence vary – they may emerge 125 
spontaneously possibly through stochastic changes in gene expression that prepare a 126 
population of pathogens for survival in varying environmental conditions (“bet 127 
hedging”). This is best described in bacteria12 but is a phenomenon recently 128 
characterised in P. falciparum13.  Furthermore, environmental signals may induce 129 
persistence such as the nutrient starvation typically encountered by C. albicans in 130 
biofilms9,14.  131 
 132 
Distinct challenges for the control of prokaryotic and eukaryotic microbial 133 
pathogens. 134 
 135 
Although bacterial and eukaryotic microbes share common features with respect to 136 
their responses to drug exposure, there are also differences that particularly challenge 137 
the control of eukaryotic pathogens. First, eukaryotic microbes are more similar to their 138 
hosts than prokaryotic pathogens in terms of their biochemistry and metabolism, 139 
genetic composition, cell architecture and biology. Consequently, drugs targeting 140 
eukaryotic microbes must focus on differences from the eukaryotic norm, or particular 141 
specialisms of each pathogen group. This restricts the cross-specificity of drugs, such 142 
that there are distinctions in sensitivity between different apicomplexans (malaria, 143 
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toxoplasma) or between the evolutionarily divergent trypanosomes, T. brucei spp. and 144 
T. cruzi.  Comprising a different evolutionary kingdom, fungi have many differences 145 
from other eukaryotic microbial pathogens, again necessitating drugs to be developed 146 
for, and targeted to, a particular pathogen. This increases the challenges for drug 147 
development and inevitably constricts the new drug pipeline. 148 
Second, many eukaryotic microbial pathogens have evolved a parasitic life 149 
style distinct from the opportunistic infections characteristic of most bacterial 150 
pathogens (but also fungi). The evolution of parasitism is often accompanied by the 151 
development of sophisticated immune evasion mechanisms, which promotes the 152 
impact of persister phenotypes described earlier. Specifically, bacteriostatic drugs can 153 
operate to clear infection in concert with the immune system15.  However, drugs that 154 
generate cytostatic rather than cytocidal responses in infection with an 155 
immunosuppressive parasite can lead to recrudescence upon the removal of drug 156 
exposure. This, in turn, can predispose the population to the selection for drug 157 
resistance. Similarly the adaptation to an intracellular life style or particular body niche 158 
can protect parasites from drug exposure, a feature shared with some bacterial 159 
pathogens that have evolved to survive in cells rather than systemically (Legionella, 160 
Mycobacteria). 161 
A third challenge relates to the clinical diagnosis and the screening for drug 162 
resistance in eukaryotic microbial pathogens16.  In bacterial infections, screening for 163 
the sensitivity to antibiotics is straightforward and routine. In contrast, eukaryotic 164 
parasites can require highly-specialised growth media and considerable growth 165 
periods to determine their susceptibility or otherwise to potential drug therapies. Also, 166 
unlike bacterial susceptibility testing where a Minimum Inhibitory Concentration (MIC) 167 
is determined, most parasitologists report EC50-values without providing the Hill slope 168 
of the growth inhibition curve or calculating the EC90 value.  It is perfectly possible to 169 
obtain a resistant line with an identical EC50 to the susceptible isolate, yet that is still 170 
resistant due to a shallower Hill slope.  As a consequence clinical diagnosis and the 171 
selection of the appropriate clinical management can be slow, or practically impossible 172 
in the context of all but the most specialised laboratories. 173 
A fourth distinction from common bacterial infections is the economic challenge 174 
of treating diseases of the developing world. Diseases such as malaria, 175 
trypanosomiasis, leishmaniasis and cryptococcosis are common in the poorest parts 176 
of the world where the economic capacity to develop or deliver treatments are very 177 
limited and restricted to philanthropic and charitable donations, or the concerted 178 
actions of multi-Government agencies. This makes the threat of drug resistance even 179 
more acute, because there is not the financial incentive to develop new drugs to 180 
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replace those to which resistance emerges. Nonetheless, certain major 181 
pharmaceutical companies are increasingly engaged in Public Private Partnerships 182 
providing access to chemical compound collections and other resources to discover 183 
and develop new drugs for neglected tropical diseases.  Excellent examples of this 184 
collaborative spirit include the Medicines for Malaria Venture (http://www.mmv.org/), 185 
the Drugs for Neglected Diseases initiative (http://www.dndi.org/) and the Tres Cantos 186 
Open Lab Foundation (http://www.openlabfoundation.org/). 187 
 One route to limit the impact of drug resistance has been the exploitation of 188 
combination therapies for parasitic infections. This approach has proved useful for 189 
cancer therapy as well as for the treatment of TB, leprosy and viral infections such as 190 
HIV. It has also been encouraged for parasitic infections, for example through 191 
artemisinin combination therapy17,18 to limit the emergence and spread of artemisinin-192 
resistant malaria, and for trypanosomes where nifurtimox/eflornithine combination 193 
therapy19 is proving more robust than eflornithine-based therapy alone. However, 194 
combination therapies for parasitic diseases require the availability of more than one 195 
effective drug or drug class, which is not always the case. Moreover, combination 196 
therapies have been often embraced only when resistance is already detected to one 197 
of the front line monotherapies, allowing multidrug resistant parasites to be selected. 198 
Here, the use of drug combinations with different pharmacokinetics in plasma, as with 199 
artemisinin and piperaquine, can limit resistance emergence20.  However, the cost of 200 
drugs for many parasites of the developing world can generate geographical 201 
discrepancy in the use of mono and combination therapies. Here, the efficacy of 202 
combination therapies can be threatened by ingression of resistant parasites selected 203 
under monotherapy. 204 
The final challenge for eukaryotic microbes that differs from many prokaryotic 205 
and viral pathogens has been the failure to formulate and use effective vaccines to 206 
prevent infection21.  Malaria research has focused intensively on vaccine development 207 
without transformative success, whereas for African trypanosomes the immune 208 
evasion mechanism employed by the parasite (antigenic variation) effectively renders 209 
vaccine approaches impossible. Other kinetoplastids have also proved challenging to 210 
produce safe effective vaccines, despite the widespread early use of ‘leishmanization’ 211 
for the cutaneous form of leishmaniasis, which has the risk of virulence in some 212 
individuals and immunosuppression22.  Fungal pathogens have their greatest impact 213 
in immunocompromised individuals rendering vaccines potentially less useful. At 214 
present there are no licenced fungal vaccines; nonetheless, there are promising 215 
developments for adhesion-like substance 3 (Als3) and secreted aspartic protease 2 216 
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(Sap2) based vaccines, although concerns have been raised over their univalency and 217 
the potential for C. albicans to circumvent their efficacy23. 218 
 219 
Drugs used against different eukaryotic microbes and examples of the 220 
resistance mechanisms against them  221 
 222 
Throughout evolution microorganisms have evolved numerous strategies to counteract 223 
cellular toxicity induced by diverse chemical stresses (xenobiotics, metals, reactive 224 
oxygen and reactive nitrogen species, etc).  Many of these generic defences have 225 
been co-opted for drug resistance. Figure 1 summarises the major therapeutic agents 226 
used to target malaria, kinetoplastid parasites and fungi, highlighting the dates of 227 
introduction and the appearance of resistance for each. The principal methods of 228 
resistance (Figure 2) involve either reduction of the free drug level at the target site of 229 
action, alterations in the drug target reducing its drug binding affinity or over-expression 230 
of the target restoring its essential function.  In the case of inhibition of a metabolic 231 
pathway, the essential end-product can be produced either by induction of an 232 
alternative pathway or by upregulation of a salvage pathway in order to obtain an 233 
essential metabolite from the host.  Downstream consequences of target inhibition 234 
include damage to DNA, proteins and lipids such that upregulation of repair pathways 235 
can also contribute to resistance.  Unlike bacteria, acquisition of resistance genes by 236 
lateral gene transfer on plasmids has not been observed for protozoan parasites or 237 
fungal pathogens. In Table 2 we summarise the drugs used to treat eukaryotic 238 
microbial pathogens, their mode of action and mechanisms of resistance where 239 
known. Below, we highlight specific examples where drug resistance or the threat of 240 
resistance challenges current control efforts. 241 
 242 
Malaria:  243 
The most successful antimalarial in history to date has been chloroquine (CQ), a 4-244 
aminoquinoline derivative of quinine (itself the world’s first mass-distributed 245 
antimalarial) and first synthesized in 193424.  CQ was cheap and remained effective 246 
for decades. However, due to massive overuse and suboptimal compliance, resistance 247 
to chloroquine emerged in Southeast Asia in 1957 and in South America in 1960, and- 248 
by the mid 1980’s- it was barely possible to use even in Africa25. Whilst disputed by 249 
some26 the leading candidate for resistance to CQ (CQR) is PfCRT (P. falciparum CQR 250 
transporter)27. However, despite reports that PfCRT functions as a chloride channel, a 251 
proton pump, an activator of Na+/H+ exchangers or a cation channel, the physiological 252 
function of PfCRT remains unclear28. Nonetheless, PfCRT is central to much 253 
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antimalarial resistance, the precise profile of which is modulated by associated 254 
mutations in other genes. 255 
Artemisinin and its derivatives are fast acting but short-lived antimalarials that 256 
have been globally successful. In particular artemisinin-based combination therapies 257 
(ACTs, e.g. artemether-lumefantrine, artesunate-amodiaquine, and 258 
dihydroartemisinin-piperaquine) were recommended by the WHO in 2001 to ensure 259 
high cure rates of falciparum malaria and to reduce the spread of drug resistance to 260 
other front line drugs. However, clinical resistance was confirmed in 200829 261 
characterised by a failure to rapidly clear parasites in patients around the Thai-262 
Cambodian border30,31. Resistant parasites were characterized by transcriptomics32, 263 
large scale whole genome sequencing (WGS) of clinical isolates33,34 and classical 264 
generation of resistant mutants by in vitro culture followed by WGS35. This pinpointed 265 
multiple independent mutations in a gene encoding a Kelch propeller protein (Kelch 266 
13) which was then causally linked to resistance by reverse genetics36,37.  Large-scale 267 
genomic epidemiological evidence suggests that artemisinin resistance is not as 268 
straightforward as the simple acquisition of mutations in kelch13.  Indeed, 269 
nonsynonymous mutations in ferredoxin, apicoplast ribosomal protein S10, multidrug 270 
resistance protein 2 and the chloroquine resistance transporter (PfCRT) also showed 271 
strong associations with artemisinin resistance29.  These mutations appear to act as 272 
markers of a genetic landscape upon which artemisinin resistance-conferring 273 
kelch13 mutations are more likely to occur.  These landscape mutations also correlate 274 
with the current geographical limits of artemisinin resistance29.  This concept is further 275 
supported by additional genomic epidemiological evidence that demonstrates many of 276 
the 20 or so mutations in kelch13 that have been implicated in the SE Asian 277 
manifestation of artemisinin resistance are also found in African PF isolates.  However, 278 
these mutations are present at no greater frequency in the African strains than other 279 
PF genes indicating a lack of selective pressure in that continent and that these strains 280 
lack the enabling genetic background observed in SE Asia38. 281 
Kelch propeller domain proteins are subcellular organisers of multiprotein 282 
complexes and indeed artemisinin resistance associated mutation of Kelch 13 results 283 
in its enhanced association with phosphatydylinositol-3-Kinase (PI3K)39.  Experimental 284 
overexpression of PI3K results in enhanced artemisinin resistance and PI3P levels are 285 
predictive of resistance to artemisinin39. In addition, upregulation of the chaperonin 286 
complexes, PROSC and TRiC, involved in the unfolded protein stress response in 287 
other eukaryotes, may contribute to artemisinin resistance32.  Worryingly, resistance to 288 
some of the various ACT regimens (involving lumefantrine and amodiaquine and 289 
PfCRT) is becoming evident40-43. However the framework for the rapid evaluation of 290 
genome evolution in the face of drugs is in place and will hopefully swiftly indicate any 291 
further potential mechanisms. 292 
 293 
 294 
Human African trypanosomiasis:  295 
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The vast majority of reported cases of HAT are caused by T. b. gambiense, with less 296 
than 2% caused by T. b. rhodesiense44.  Treatment involves either pentamidine or 297 
suramin for stage 1 infection (before CNS involvement) whereas melarsoprol, 298 
eflornithine or nifurtimox/eflornithine combination therapy are used once the parasite 299 
crosses the blood-brain barrier2, the latter combination therapy reducing the duration 300 
of treatment regimens.  Given the limited chemotherapeutic options for the treatment 301 
of HAT (Table 2), drug resistance could seriously compromise efforts to eliminate this 302 
epidemic disease as a public health problem44. Fortunately, resistance emergence for 303 
pentamidine has not been significant, despite continuous use of pentamidine since the 304 
1940s, including a mass chemoprophylactic campaign in the 1950s in the then Belgian 305 
Congo. However, cross resistance to pentamidine and melarsoprol, used for stage 2 306 
of infection, is frequently observed. Melarsoprol is a trivalent melaminophenyl arsenical 307 
which has a propensity to react covalently with vicinal dithiols, including the parasite-308 
specific dithiol, trypanothione45, to form a cyclic complex known as MelT46. Melarsoprol 309 
has a high incidence of severe (lethal) toxicities and high rates of treatment failures 310 
have been reported in the Democratic Republic of Congo, Uganda, Angola and 311 
Sudan2.  Although therapeutic failure does not necessarily equate with drug resistance, 312 
it appears that the high relapse rate in northwest Uganda is associated with reduced 313 
susceptibility to melarsoprol47,48. The recent report that the aquaglyceroporin AQP2 314 
appears to function as a transporter for large drugs such as pentamidine and 315 
melarsoprol was surprising given that Aquaglyceroporins are channels facilitating the 316 
passive transport of water and small neutral molecules across cell membranes.  317 
Nonetheless, there is strong evidence that AQP2 is indeed synonymous with the high 318 
affinity pentamidine transporter (HAPT1)49, with a recent report indicating that 319 
pentamidine binds and inhibits the transporter and is then internalised via 320 
endocytosis50. 321 
 322 
Chagas’ disease:  323 
For Trypanosoma cruzi, an intracellular parasite with a wide tissue tropism, infection 324 
has three phases: an acute phase associated with high parasitaemia; an asymptomatic 325 
(indeterminate) phase lasting anywhere between 10-30 years, where parasitaemia is 326 
controlled by the immune response; and a chronic phase in about 30-40% of patients 327 
characterised by either cardiac disease or digestive disease (mega-oesophagus and 328 
mega-colon). For treatment, benznidazole and nifurtimox have significant activity in 329 
the acute phase51 and benznidazole also eliminates parasitaemia in the indeterminate 330 
and chronic phases of the disease52,53.  However, a large multi-centre, randomized trial 331 
of benznidazole for chronic Chagas’ cardiomyopathy failed to significantly reduce 332 
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cardiac clinical deterioration through 5 years follow-up53.  Whether this is due to 333 
differences in drug susceptibility, pharmacokinetic/pharmacodynamic issues or the 334 
pathophysiology of the disease is not known.  The results of two recent clinical trials 335 
with azole ergosterol inhibitors, posaconazole and E1224 (a pro-drug of ravuconazole) 336 
have been equally disappointing52,54,55. 337 
 338 
 339 
Visceral leishmaniasis:  340 
Treatment of visceral leishmaniasis (VL), cutaneous and mucocutaneous 341 
leishmaniasis is limited to four main drugs: pentavalent antimonial complexes (sodium 342 
stibogluconate and meglumine antimonate); amphotericin B (as deoxycholate or 343 
liposomal formulations); the aminoglycoside paromomycin; and the 344 
alkylphosphocholine miltefosine56,57.  Treatment varies according to geographical 345 
location, the immune status and other co-morbidities of the patient, and the disease 346 
classification58. 347 
Of these treatments, widespread resistance to antimonial drugs is specific to 348 
Southern Asia and not in Sub-Saharan Africa or Brazil.  Indeed, antimonial drugs are 349 
not recommended in India or Nepal due to treatment failures commencing in the 1990s 350 
and now reported to be as high as 60% in some regions59.  This has been attributed to 351 
inappropriate treatment in an unregulated private health system or to the use 352 
substandard antimonial drugs.  However, Southern Asia is the only region where 353 
arsenic exposure and widespread antimonial resistance co-exist.  Thus, environmental 354 
pollution and exposure of patients to arsenic in food and drinking water was proposed 355 
as an alternative hypothesis60.  Arsenic and antimony are both metalloids and selection 356 
of leishmania parasites for resistance to trivalent arsenic results in cross-resistance to 357 
trivalent antimony in vitro61, but its physiological relevance was uncertain.  Chronic 358 
exposure of infected mice to arsenic in drinking water at environmentally relevant 359 
levels demonstrated that it is possible to generate resistance to pentavalent antimony 360 
in vivo62.  A retrospective clinico-epidemiological study identified a trend towards 361 
increased treatment failure in arsenic exposed patients, but failed to reach statistical 362 
significance63. 363 
   364 
Resistance to antimonials is multifactorial and most of the mechanisms shown in 365 
Figure 2 have been implicated in Leishmania.  Studies on experimental and clinical 366 
resistant isolates strongly support the hypothesis that trypanothione plays a pivotal role 367 
in antimonial resistance.  However, none of the following mechanisms are universal in 368 
resistant isolates.  Decreased biological reduction of SbV to SbIII has been reported in 369 
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resistant leishmania amastigotes64 and two candidate “antimony reductases” 370 
identified, although genetic65,66 and proteomic studies67,68 have not identified any 371 
changes in either TDR169 or ArsC70.  The mechanism of uptake of SbV is not known, 372 
but modulation of expression of aquaglyceroporin 1 (AQP1) affects SbIII susceptibility71-373 
73.  AQP1 copy number and expression levels correlate with susceptibility to SbIII in 374 
some, but not all, clinical isolates74,75.  However, interpretation of this observation is 375 
complicated by the fact that AQP1 is located on chromosome 31, which is frequently 376 
trisomic or tetrasomic76 in these mosaic aneuploid parasites77. Upregulation of 377 
trypanothione and ancillary biosynthetic pathways has also been observed in 378 
genomic65,66 and metabolomic78,79 studies. MRPA is responsible for ATP-dependent 379 
efflux of SbIII as a thiol conjugate into membrane vesicles80 and a homodimeric ABC 380 
half-transporter (ABCI4) is one possible candidate for efflux across the plasma 381 
membrane81.   382 
Miltefosine, the only oral treatment for VL, was first approved for use in India in 383 
2002.  However, a decade on there is an increasing rate of clinical relapse82,83, which 384 
threatens to undermine the Kala-Azar Elimination Program in the Indian subcontinent. 385 
Stable resistance is readily generated in the laboratory with no cross-resistance to 386 
other anti-leishmanial drugs84,85.  387 
 388 
Fungi:  389 
Several classes of antifungals are used clinically (Table 1, Table 2) – each with very 390 
different drug resistance profiles. The oldest antifungals are the polyene macrolide 391 
antibiotics, exemplified by amphotericin B, which remains a front-line choice of a broad 392 
spectrum agent for fungal infections of unknown aetiology. Amphotericin deoxycholate 393 
has significant nephrotoxicity which is significantly ameliorated in lipid carrier 394 
formulations such as AmBisome, which also has potent anti-Leishmania activity. As 395 
with other eukaryotic pathogens, resistance to antifungal drugs has become an 396 
increasing important clinical problem86,87.  A few recognised cases exist of inherent 397 
resistance of specific fungi to specific antifungals, but mostly resistance is due to 398 
induced changes and mutations.  399 
The imidazoles and more modern triazoles (collectively known as the “azoles”) 400 
constitute the main class of antifungals used in the treatment of infections. Various 401 
modifications of the triazole ring have generated a series of antifungals including 402 
fluconazole (used mainly in the treatment of Candida infections), and itraconazole, 403 
voriconazole, posaconazole, ravuconazole and the recently licenced isavuconazole 404 
which have improved activity against Aspergillus and filamentous fungal species.  405 
These compounds have important differences in antifungal potencies, spectrum of 406 
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activities, bioavailability, drug interactions and toxic potential.  For example, some 407 
patients treated with voriconazole suffer from photosensitivity and an elevated risk of 408 
skin carcinoma88.  Other sterol inhibitors include the allylamines squalene epoxidase 409 
inhibitors and phenylmorpholine Erg24 D14 reductase and Erg2 D8-D7 isomerase 410 
inhibitors that are used topically against dermatophytic infections for which clinical 411 
resistance is low.   412 
Although some fungi such as Candida krusei are inherently azole resistant, 413 
multiply triazole resistant strains are now emerging89,90 as well as strains with cross 414 
resistance to azoles and echinocandins suggesting worrisome multi-drug resistance 415 
(MDR) phenotypes in medically important fungi91.  A threat from multi-azole resistant 416 
strains of A. fumigatus may have arisen under the selective pressure of agricultural 417 
azole fungicides and subsequent transmission of azole resistant strains to the clinic by 418 
spore dispersal92-95. The prevalence of these alleles is increasing in Europe and now 419 
in other parts of the world90,96,97.  In Candida mutants harbouring azole resistance have 420 
a fitness deficit98; however, MDR strains of Aspergillus do not seem to have 421 
significantly decreased fitness implying they may become stably represented in the 422 
environment. 423 
The most recently developed major class of antifungal are the echinocandin 424 
antibiotics of which caspofungin, micafungin and anidulafungin are used clinically.  425 
These have similar pharmacokinetic properties although a new echinocandin (CD101- 426 
formerly Biofungin) is in clinical trials and has improved stability in vivo and requires 427 
less frequent i.v. dosing. Echinocandins are fungicidal against Candida species and 428 
fungistatic or fungicidal against Aspergillus causing hyphal or bud tip lysis but they are 429 
not efficacious against Pneumocystis jiroveci and some other species. 430 
Hsp90-mediated changes in drug tolerance have also been implicated in 431 
determining echinocandin sensitivity99.  Recently, multi-drug azole/ echinocandin 432 
resistance has been identified in fungi and this is particularly frequent in strains of 433 
C. glabrata which is common in patients with haematological malignancies and solid 434 
tumours100,101.  These MDR strains of C. glabrata become reliant on i.v. amphotericin 435 
treatment, and since this agent has poor penetration into urine such infections are 436 
essentially untreatable. 437 
 438 
 439 
Outstanding challenges and future prospects 440 
 441 
This review began by highlighting the similarities and differences between drug 442 
resistance emergence in prokaryotic and eukaryotic microbes. The control of the 443 
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emergence of drug resistance for eukaryotic microbial pathogens also has similarities 444 
and distinctions from prokaryotic drug resistance, and our challenge for the future is to 445 
ensure best practice is employed for both groups. One effective mechanism to control 446 
drug resistance spread in bacterial pathogens is the application of appropriate 447 
antibiotic stewardship, applying the right drug at the right dose, at the right time, for the 448 
right duration. This approach operates effectively where there is well-regulated 449 
healthcare, effective and rapid screening, a selection of available drugs as contingency 450 
and the necessary education and engagement between the patient and healthcare 451 
provider. Moreover, bacterial drug resistance is a global phenomenon where 452 
resistance selected through poor stewardship in one geographical area may be 453 
contained by stringent practices in other areas, or combatted by an investment in new 454 
pharmaceutical development in wealthy countries. These containment measures are 455 
inevitably less effective where primary care is limited or too expensive, education is 456 
lacking or where the diseases involved do not have direct impact in the developed 457 
world. In consequence, the limitation of many eukaryotic pathogens to the poorer parts 458 
of the world makes a co-ordinated response to resistance emergence more difficult to 459 
achieve. 460 
 The drivers of resistance emergence are also more difficult to mitigate for many 461 
eukaryotic pathogens. As highlighted earlier, drug provenance and effective delivery 462 
is a significant challenge in the developing world. The latter is a particular challenge 463 
for prospective mass drug administration programmes where delivery to a population 464 
on a broad or local scale, if incomplete, can counteract its intention to contain the 465 
spread of existing resistance in target regions. A further complication in low and 466 
middle-income countries is the effects of co-infection or malnutrition in populations 467 
treated with drugs targeting a particular pathogen (discussed in 102). Notably, the 468 
pharmacokinetic behaviour of drugs in malnourished individuals may be variable and 469 
unpredictable leading to inadvertent under-dosing, driving resistance emergence. 470 
When combined with immunosuppression induced by many parasites, or the hospital-471 
induced immunosuppression of patients that become susceptible to fungal infection, 472 
drug concentrations that would clear infections in the context of a robust immune 473 
system may fall short in its absence. The ecological balance between distinct 474 
pathogens in patients with coinfections can also lead to unanticipated consequences, 475 
where the removal of one pathogen can create a niche exploited by a distinct pathogen 476 
or where the normal interactions between pathogens with each other, and with the 477 
immune system, is perturbed with drug pressure. The resistance mechanisms selected 478 
in drug treated populations can also alter pathogen phenotypes with the risk of 479 
enhanced virulence. 480 
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Although the factors that drive drug resistance are well known, it remains 481 
essential to identify when drug resistance arises and to respond rapidly and effectively. 482 
As with health care, surveillance is a key challenge for diseases in the developing 483 
world, where populations may be inaccessible, reluctant to engage or where treatment 484 
failure can have multiple causes beyond the emergence of drug resistance. Moreover, 485 
resistance can show considerable variation amongst populations or in different 486 
geographical settings. Here, accurate and rapid detection is critical to understand 487 
resistance epidemiology and thereby the best treatment to deliver, but this can be 488 
difficult to achieve. Despite this, developments in field PCR assays and next generation 489 
sequencing permit the sensitive identification and tracking of emergent resistance, 490 
allowing earlier control responses than could be previously achieved. Hence, an 491 
integration of improved therapeutic delivery and treatment monitoring are critical 492 
control points to reduce resistance emergence, in tandem with the discovery of the 493 
relevant resistance mechanisms and the search for new drug therapies. These 494 
combined approaches span from the individual scientific researcher to clinician, to 495 
health agency, to government and population, which must be well-integrated, and alert, 496 
with effective and rapid communication between distinct levels to allow appropriate 497 
responses to be put into action if needed.  498 
Fortunately, whilst drug resistance is emerging in many eukaryotic microbial 499 
pathogens, new tools and methodologies are being developed to (i) predict resistance 500 
mechanisms, (ii) to identify modes of drug action and potential escape pathways  and 501 
(iii) to understand pathogen biochemistry as a means to discover new potential 502 
therapies. With respect to drug resistance, the advent of cost-effective and rapid 503 
genome resequencing allows signatures of selection to be identified103-106, whilst 504 
genome-wide RNAi screens allow the mapping of resistance pathways107,108, and 505 
overexpression libraries109 can assist with drug target deconvolution through selective 506 
screens. These genetic tools are complemented by improvements in proteomics such 507 
that adaptations accompanying drug resistance can be pinpointed, providing 508 
information on resistance mechanisms, and potential diagnostic tools to detect 509 
resistance emergence110.  Combined with the improved sensitivity and resolution of 510 
metabolomics analysis111, biochemical pathways can also be mapped in the context of 511 
drug exposure, allowing bypass mechanisms to be highlighted, if present. These each 512 
provide the essential early warning systems necessary to identify and combat the 513 
spread of drug resistance.  Furthermore, certain combination therapies might offer 514 
novel transmission blocking strategies: very recently resistance to the antimalarial 515 
atovaquone, a component (with proguanil) of the widely used and successful treatment 516 
marketed as Malarone, has been further characterised.  Resistance mutations that 517 
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appear during the target blood stage infection localise to the mitochondrial protein 518 
cytochrome b, one of the few proteins encoded by the highly reduced Plasmodium 519 
mitochondrial genome.  All atovaquone resistance mutations examined generate a 520 
deficient mitochondrion and a parasite that, whilst viable in the blood, is incapable of 521 
development in the mosquito and thereby cannot be transmitted112.  Thus despite the 522 
fact that resistance to atovaquone might arise repeatedly, each incident is isolated.  523 
Drugs that target cytochrome b could form part of combination therapies that are self-524 
limiting in terms of spread of drug resistance and may delay any transmission of 525 
resistance that arises to the drug it is partnered with.  526 
 527 
Concluding remarks 528 
 529 
Drug resistance in eukaryotic microbes is an increasing global problem that threatens 530 
the advances in healthcare over the last 50 years. This mirrors the situation for 531 
bacterial and viral pathogens but is particularly acute given the abundance of 532 
eukaryotic pathogens in the poorest regions of the world. These countries have the 533 
least capacity to respond to resistance emergence through the development of new 534 
drugs vaccines and diagnostics, whilst developed countries lack financial incentives to 535 
assist. Nonetheless, there are opportunities to respond to this threat due to the distinct 536 
biology of many major eukaryotic pathogens and the discoveries made in basic 537 
research focused on their biology. Furthermore, many eukaryotic microbes are 538 
arthropod-borne diseases, such that targeting transmission can be a route to pathogen 539 
control not available for opportunistic pathogens. This can take the form of 540 
transmission-blocking vaccines or drugs targeting Plasmodium113 or the application of 541 
vector control measures such as insecticide impregnated bed nets114, peri-domestic 542 
and indoor residual insecticide spraying114,115, tsetse traps116, or improved housing117. 543 
Sterile insect release is also a route to limiting the vector population and so restricting 544 
disease spread118,119. Eukaryotic microbes have also, like some bacterial pathogens, 545 
been found to show co-operative and social behaviours to optimise their establishment 546 
and transmission in their hosts or vectors120,121.  These social responses can control 547 
parasite density or the development of transmission stages122-124, such that blocking or 548 
mimicking signals for communication or their transduction pathways provides new 549 
routes to limit the impact of the pathogens using strategies that might be less 550 
susceptible to resistance emergence. 551 
Whether or not new targets or new approaches can be identified, there is a real 552 
need to optimise the delivery and deployment of drugs.  Control of drug quality, 553 
distribution and supply of cost-effective drugs is crucial.  Also the application of both 554 
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epidemiological modelling and evolutionary theory to guide drug treatment policies is 555 
important in prolonging the life span of drugs and thereby maximising the return on the 556 
considerable cost associated with developing and introducing a new drug.  Targeted 557 
therapy as opposed to mass drug administration is key to limiting the emergence of 558 
resistance, or containing resistance when it is detected. This requires an integration of 559 
epidemiology, diagnosis, detection and supply chain control as well as investment in a 560 
pipeline of new therapeutics ready to be deployed when resistance inevitably emerges.  561 
Only through slowing resistance emergence and accelerating new drug discovery will 562 
the control successes achieved against eukaryotic microbial pathogens be sustained. 563 
  564 
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Table 1.   565 
Diseases caused by eukaryotic microbes, their vectors and front-line treatment 566 
options. Several of the parasitic pathogens are arthropod-transmitted, and in these 567 
cases the responsible vector is shown. Fungal pathogens are predominantly 568 
opportunistic. 569 
 570 
Table 2 571 
Modes of action and mechanisms of drug resistance in eukaryotic microbes 572 
 573 
Figure Legends 574 
 575 
Figure 1 Timelines for emergence of drug resistance in parasitic diseases (A) 576 
and Fungi (B). The darker bar represents the time from first widespread clinical use 577 
to the first year drug resistance was suspected or confirmed.  The shading indicates 578 
that certain drugs are still in use for particular indications or in specific geographical 579 
locations. Abbreviations: S-P, sulfadoxine-pyrimethamine; PPQ, piperaquine; ACTs, 580 
artemisinin combination therapies; NECT, nifurtimox eflornithine combination therapy; 581 
L-AMB, liposomal amphotericin B; MLT, miltefosine. For fungal pathogens, insensitive 582 
or resistant strains have been identified shortly after the introduction of all of the major 583 
classes of antifungal agents.  In the case of amphotericin B, there remains very little 584 
resistance – and differences in sensitivity mainly reflect the relative inherent sensitivity 585 
of different species to this agent. 586 
 587 
 588 
Figure 2 Molecular mechanisms of drug-resistance.  589 
Eukaryotic microbial pathogens can exhibit drug resistance through reducing the 590 
overall intracellular concentration of the drug (less uptake, more efflux), by inactivating 591 
or failing to activate the drug, or by sequestering the drug away from its target. 592 
Resistance can also be mediated by reducing affinity of the drug for the target by 593 
mutation or by reducing the drug effect by overexpression of the target. Salvage and 594 
by-pass pathways can also lower the overall impact of the drug action, as can the 595 
activation of pathways in order to repair any damage caused. 596 
  597 
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Table 1.  Diseases caused by eukaryotic microbes, their vectors and front-line treatment options 
Disease Pathogen 
group 
Vector Pathogen Front-line treatments a 
Malaria apicomplexan Anopheline 
mosquitoes 
Plasmodium falciparum Uncomplicated P. falciparum malaria: 
Artemisinin combination therapies (ACTs) 
• Artemether + lumefantrine 
• Artesunate + amodiaquine 
• Artesunate + mefloquine 
• Dihydroartemisinin + piperaquine 
• Artesunate + sulfadoxine + pyrimethamine 
Severe malaria: 
Parenteral (or rectal, children < 6 years) artesunate 
followed by oral ACT (i.m. artemether or i.m. quinine if 
artesunate unavailable) 
P. vivax, P. ovale, P. 
malariae or P. knowlesi 
Blood stage infections: 
Chloroquine (except in areas of chloroquine resistance) 
ACTs (except pregnant women and infants < 6 months) 
Radical cure of liver (hypnozoite) infection: 
Primaquine (close medical supervision with G6PD-
deficient patients) 
African 
trypanosomiasis 
kinetoplastid Tsetse flies Trypanosoma brucei 
gambiense (chronic 
form) 
Haemolymphatic stage (no CNS involvement): 
Pentamidine (i.m.) 
CNS stage: 
Nifurtimox (oral) / eflornithine (i.v.) combination therapy 
(NECT) 
(Melarsoprol if NECT unavailable) 
T. b. rhodesiense 
(acute form) 
Haemolymphatic stage (no CNS involvement): 
Suramin (i.v.) 
CNS stage: 
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Melarsoprol (i.v.) 
American 
trypanosomiasis 
kinetoplastid Triatomine 
bugs 
Trypanosoma cruzi Benznidazole 
Nifurtimox 
Leishmaniasis kinetoplastid Phlebotomine 
sandflies 
Visceral disease 
Leishmania donovani  
L. infantum  
Mucocutaneous 
disease 
L. braziliensis 
L. panamensis  
Cutaneous disease, 
e.g. 
L. major  
L. tropica 
L. mexicana 
L. amazonensis 
Visceral disease: 
Amphotericin B (as liposomal or deoxycholate complex, 
i.v.) 
Miltefosine (oral, contraindicated in pregnancy) 
Paromomycin (i.m.) 
Sodium stibogluconate (SSG) or meglumine 
antimonate, parenteral (except India and Nepal)  
SSG plus paromomycin (East Africa) 
Mucocutaneous: 
SSG (systemic) 
Cutaneous: 
SSG (intralesional) 
Paromomycin (ointment) 
Miltefosine 
Invasive 
Candidiasis 
fungal opportunistic Candida albicans 
Candida glabrata 
Candida parapsilosis 
Echinocandins, Fluconazole, Liposomal Amphotericin B 
Aspergillosis fungal opportunistic Aspergillus fumigatus Voriconazole (Amphotericin B formulations; 
caspofungin; micafungin; posaconazole; itraconazole) 
Pneumocystis 
pneumonia 
fungal opportunistic Pneumocystis carinii Sulfamethoxazole-Trimethoprim (clindamycin-
primaquine)  
Cryptococcal 
meningitis 
fungal opportunistic Cryptococcus 
neoformans 
Amphotericin B plus flucytosine 
Amphotericin B plus fluconazole 
 
a Second line treatment options are given in parentheses 
Data from WHO 58,125-127 and other sources 57,128,129  
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Table 2. Modes of action and mechanisms of drug resistance in eukaryotic microbes 
 
Pathogen Drug and date of 
resistance 
reported 
Drug class and Mode of 
action 
Resistance mechanism 
Plasmodium Chloroquine (CQ) 
 
1957 (SE Asia) 
1960 (S America) 
Mid 1980s (Africa) 
4-Aminoquinoline  
 
Chloroquine interferes with 
the detoxification of haem 
into chemically inert 
haemozoin resulting in 
accumulation of toxic CQ 
ferric haem complex and 
subsequent parasite 
lysis130.   
K76T27 mutation in a Digestive Vacuole-sited, ATP-dependent, 10 
transmembrane domain transporter PfCRT (P. falciparum CQR 
transporter)27; a range of more than 30 different mutations might interact 
epistatically131-133.  These stimulate the active efflux of CQ by mutant 
PfCRT or the passive efflux of diprotonated CQ133.  
 
Other genes contributing to resistance include: the P multidrug resistance 
transporter 1 (PfMDR1) homologue; multipass transmembrane 
transporter CG2; and PfNHE1 and a sodium hydrogen antiporter also 
associated with quinine resistance134. The specific genetic background of 
the parasite and the range of mutations in genes other than PfCRT are 
also key to the manifestation of CQR135.  
 
An independent mutation in PfCRT (C350R) can reverse CQR and also 
increase susceptibility of the parasite to other antimalarials (mefloquine, 
quinine and lumefantrine but not piperiquine136).  
The mutation N326D confers increased resistance to the antimalarial 
amodiaquine40  
Mefloquine 
 
1982 (Thailand) 
Quinoline-4-methanol  
 
Blockade of haemozoin 
formation and binding to 
phospholipids 
PfMDR1 is associated with mefloquine resistance137 but may also 
modulate CQR through compensatory mutations that counteract PfCRT 
mutations that compromise parasite fitness138. 
Artesunate 
Dihydroartemisinin 
Artemether 
 
Sesquiterpene lactone 
endoperoxides.  
 
Dormancy resulting in an extended ring stage phase of development in 
the erythrocyte promotes resistance30-32. 
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200829 (SE Asia) Form a carbon-centred 
free radical or reactive 
electrophilic intermediate 
that alkylates a number of 
malaria proteins139 after 
activation by haem or free 
iron. 
Multiple independent mutations in a gene encoding a Kelch propeller 
protein (Kelch 13) confer resistance33-37. This results in its enhanced 
association with phosphatydylinositol-3-Kinase (PI3K), which is 
subsequently under-ubiquitinated and accumulates along with its lipid 
product, phosphatidylinositol-3-phosphate (PI3P).   
 
The specific genetic background of the parasite and the range of 
mutations in genes other than kelch13 may also be key to the 
manifestation of resistance to artemisinin33 
Sulfadoxine / 
Pyrimethamine  
 
1967 (Thailand); 
1980s (Africa) 
 
 
Antifols.  
 
Sulfadoxine – inhibition of 
dihydropteroate synthase 
(DHPS) 
Pyrimethamine – inhibition  
of dihydrofolate reductase 
(DHFR) 
Synergistic effect on 
thymidylate synthesis 
Decreased affinity of both drugs for their respective targets.  
 
Resistance to sulfadoxine involves DHPS point mutations., DHPS 
variant A437G confers moderate resistance, with the additional 
mutations S436F plus A613S conferring a high level resistance140. 
   
Pyrimethamine clinical resistance involves DHFR point mutations at 
S108N in Africa and SE Asia. Additional mutations that confer high level 
resistance are N51I and C59R141 
 
Increased GTP-cyclohydrolase (CNVs) enhances folate biosynthesis 
compensating for loss of fitness141 
Proguanil DHFR inhibitor High level resistance to cycloguanil (a metabolite of proguanil) involves 
DHFR mutation of serine 108 to threonine. The triple mutations (C59R, 
S108N and I164L) confer cross resistance to both pyrimethamine and 
cycloguanil142. 
 Atovaquone 
(in combination 
with proguanil for 
prophylaxis or 
treatment) 
Cytochrome b inhibitor Effective resistance to atovaquone involves one of a range of mutations 
in cyt b most commonly Y268S. Other mutations associated with such 
resistance include I258M, Y268C, M133I and V259L143 
Suramin Naphthylamine trisulfonic 
acid 
Laboratory-generated resistance mediated through the silencing of 
invariant surface glycoprotein (ISG75), the AP1 adaptin complex, 
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African 
Trypanoso
mes 
 
Mode of action unknown 
lysosomal proteases and major lysosomal transmembrane protein, as 
well as spermidine and N-acetylglucosamine biosynthesis108. 
Pentamidine 
 
Clinical resistance 
is not significant. 
Diamidine 
 
Mode of action unknown 
Resistance is associated with loss of uptake on the P2 
adenine/adenosine transporter144, (AT1)145.   
 
Cross-resistance between melaminophenyl arsenicals and diamidines 
is mediated by aquaglyceroporin 2 (AQP2) 146. A chimeric AQP2/AQP3 
gene is associated with cross resistance to melarsoprol and 
pentamidine in laboratory-generated49,146,147 and clinical isolates148,149 
Melarsoprol 
 
Treatment failures 
have been reported 
in the Democratic 
Republic of Congo, 
Uganda, Angola 
and Sudan2 
Trivalent melaminophenyl 
arsenical.  
 
Forms a cyclic complex 
with trypanothione known 
as MelT46. Inhibits 
trypanothione reductase 
and no doubt other 
targets. 
Resistance is associated with loss of uptake on the P2 
adenine/adenosine transporter144,145.  A non-functional mutant has been 
identified in melarsoprol-resistant field isolates150. 
 
See also AQP in pentamidine section.  
Eflornithine 
(difluoromethyl-
ornithine) 
Fluorinated amino acid. 
 
Mechanism-based 
inhibitor of ornithine 
decarboxylase, required 
for biosynthesis of 
polyamines and 
trypanothione.   
Laboratory-generated resistance is due to loss of a non-essential amino 
acid transporter151,152. There is no detected resistance in 
T. b. gambiense, but there is inherent resistance in some clinical 
isolates of T. b. rhodesiense2. 
 Nifurtimox 
 
(poor efficacy as 
monotherapy; used 
in combination 
therapy with 
Nitrofuran  
 
Prodrug activated by an 
oxygen-insensitive 
mitochondrial 
nitroreductase (NTR)153 to 
A genome-scale RNA interference screen identified NTR and a number 
of other genes possibly associated with NTR function108. NTR is also 
the key resistance determinant in laboratory-generated lines156,157 
showing cross resistance to fexinidazole an oral nitro-imidazole 
currently undergoing Phase II/III clinical trials for HAT. 
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eflornithine 
[NECT]) 
form highly reactive drug 
metabolites154 that kill 
trypanosomes via 
unknown mechanisms155.   
South 
American 
Trypanoso
mes 
Benznidazole, 
Nifurtimox 
 
(natural resistance 
in some T.cruzi 
isolates) 
Nitroheterocyclics 
 
Benznidazole is activated 
by mitochondrial 
NTR153,158 to form 
electrophilic drug 
metabolites159,160 
Drug efflux via an ABCG-like transporter161 
 
The NAD(P)H flavin oxidoreductase (old yellow enzyme) is 
downregulated in resistant lines162,163.  However, this enzyme does not 
reduce benznidazole and only reduces nifurtimox under anaerobic 
conditions164.  
Visceral 
Leishmania
sis 
Sodium 
stibogluconate, 
Meglumine 
antimonite 
 
1990s widespread 
resistance in India 
and Nepal.  Not 
widespread in Sub-
Saharan Africa or 
Brazil 
Pentavalent antimonials  
 
SbV is reduced to SbIII to 
attack intracellular 
amastigotes. Likely to bind 
multiple targets including 
trypanothione 
reductase165,166, 
tryparedoxin peroxidase167 
and CCHC Zinc finger 
proteins166.  
Selection for resistance to trivalent arsenic results in cross-resistance to 
trivalent antimony in vitro61, and in vivo62. Resistance is multifactorial 
through several mechanisms: 
 
• Decreased reduction of SbV to SbIII 
• SbIII is taken up via an aquaglyceroporin73 and modulation of 
expression of aquaglyceroporin 1 affects SbIII susceptibility71-73.   
• Elevated Intracellular trypanothione levels168 or increased 
biosynthetic potential65,66,78,79 . 
• Increased levels of tryparedoxin peroxidase confer resistance to 
SbIII 169 and are found in clinical resistant isolates167 
• MRPA (also known as PgpA or ABCC3), a member of the ATP-
binding cassette (ABC) transporters, is amplified in some resistant 
lines170-172 and sequesters SbIII in an intracellular vacuolar 
compartment close to the flagellar pocket80. 
• chaperones and stress related proteins are upregulated67,68 , 
potentially reducing or repairing cellular damage induced by 
antimonials173 
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 Paromomycin Aminoglycoside 
 
Inhibition of protein 
synthesis 
Added to WHO essential medicines list in 2007. No significant clinical 
resistance. Laboratory-derived resistant lines show decreased drug 
uptake and increased expression of ribosomal proteins174. 
 Miltefosine 
 
2012 (Indian 
subcontinent) 
Alkylphosphocholine 
 
Miltefosine significantly 
perturbs lipid 
metabolism175-177, but the 
targets and precise 
mechanism of action are 
not fully understood178 
Resistance involves either: loss-of-function mutations or under-
expression of an aminophospholipid translocase (LdMT)179-181 or its 
regulatory subunit LdRos3182; or drug efflux by ABC transporters183,184. 
Laboratory-generated resistant lines show alterations in lipid 
metabolism and gene expression 85,185, but WGS in another study 
identified mutations only in the miltefosine transporter, pyridoxal kinase 
and an α-adaptin-like protein176. 
 Amphotericin B 
(deoxycholate or 
liposomal 
formulation) 
Polyene macrolide 
antibiotics 
 
See below 
No significant clinical resistance reported 
Fungi Amphotericin B, 
amphotericin 
deoxycholate 
Polyene macrolide 
antibiotics;  
 
Binds ergosterol more 
avidly than human 
cholesterol disrupting the 
semipermeable membrane 
causing leakage of 
essential metabolites and 
the collapse of 
electrochemical gradients.  
Binding of low density 
lipoprotein receptors and 
amphotericin-mediated 
oxidative damage may 
also contribute. 
Laboratory mutants with lower ergosterol content are less sensitive to 
amphotericin B, but are rare clinically.  Aspergillus terreus is intrinsically 
less amphotericin sensitive but resistant strains have a normal 
ergosterol content suggesting that membrane permeability may not be 
the only mechanism of amphotericin action186. Binding to ergosterol 
might contribute to its mode of action187. 
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Fluconazole, 
Itraconazole, 
Voriconazole, 
Posaconazole, 
Ravuconazole, 
Isavuconazole 
Azoles; 
Bind haem-groups and 
inhibit the P450–mediated 
14α-demethylation 
(Erg11p or Cyp51p) of 
lanosterol in the ergosterol 
biosynthetic pathway. 
Leads to impaired 
membrane permeability, 
membrane protein action 
and cell wall synthesis188. 
Resistance involves the overexpression of drug efflux pumps and point 
mutations in the target ERG11 / CYP51A gene product, along with 
promoter mutations in these genes189-191.  Changes in the levels of three 
main efflux pumps Cdr1, Cdr2 and Mdr1 and mutations in the genes 
encoding the Tac1, Upc2, Pdr1 and Mrr1 transcription factors required 
for efflux pump upregulation, represent major causes of decreased drug 
sensistivity192,193.  This type of azole resistance can be acerbated by 
isochromosome formation and aneuploidy which can increase the copy 
number of key resistance genes such as ERG11 and TAC1194-196 .  
Interference with RNA polymerase II interacting Mediator-complex can 
re-sensitize Pdr1 dependent regulation of drug efflux pumps197  
Chaperone Hsp90 can mitigate against stress induced damage198 and 
also contribute to multidrug resistance with Echinocandins. 
TR34/L98H and the more recently identified TR46/Y121F/T289A alleles 
that confer clinical azole resistance are likely to have arisen from 
environmentally generated mutations 
Caspofungin, 
Micafungin, 
Anidulafungin, 
Cd101 (formerly 
biofungin) 
Echinocandins; 
Cyclic hexapeptides with 
an antifungal bioactive 
lipid side chain that binds 
the fungal specific β-1,3-
glucan synthase Fks cell 
membrane proteins, 
disrupting cell wall 
integrity.   
Resistance through point mutations in two major hotspots in the β-1,3 
glucan synthase genes FKS1 - and, in C. glabrata, FKS286,101,199, these 
reducing drug binding57,181,182. 
Upregulation of cell wall chitin can protect cell wall damage 184-186. 
Hsp90 chaperone can mitigate against stress induced damage170 
Flucytosine (5-
fluorocytosine) 
Fluoropyrimdines; 
converted to 5-fluorouracil 
Resistance results from mutations in the genes encoding cytosine 
permease transporter, cytosine deaminase, which converts 5-FC to 5-
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by cytosine deaminase 
which becomes 
incorporated into RNA 
resulting in inhibition of 
DNA synthesis. 
fluorouracil or the uracil phosphoribosyl transferase required to convert 
5-fluorocytosine into a substrate for nucleic acid synthesis200. Their 
impact is lessened by the use of 5FC in combination therapy. 
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